Authors
Xinyi Zeng, Xinhua Zeng, Weichang Huang, Sujun Li
Published in
Carbohydrate polymers. Volume 393. Pages 125926. Dec 01, 2026. Epub Oct 09, 2026.
Abstract
Polysaccharides from fungi, plants and algae have been adjunctive cancer immunotherapies for decades, yet clinical impact lags the preclinical literature. This review treats them as structure-informed modulators of selected components of the tumour immune microenvironment, not as nonspecific biological response modifiers. We organize the evidence as one causal chain: fine structure influences which pattern-recognition receptor is engaged, receptor engagement shapes a signalling programme, and that programme shapes effector output; most preparations engage more than one receptor, so a response reflects their combined signalling. We advance three arguments. First, immunomodulation can be bidirectional: TLR4-NF-κB reportedly drives activating and suppressive outputs depending on structure, dose and tissue context, though suppressive outputs are documented only outside tumour models. Second, the most consequential recent evidence concerns relief of immunosuppression: PD-L1 downregulation, depletion of myeloid-derived suppressor cells, interference with regulatory T cells and the IL-35 axis, and sensitisation to checkpoint blockade. Third, translational failure reflects addressable barriers: batch heterogeneity, absent receptor-specific genetics, and no quantitative structure-activity model. Clinical evidence - two long-approved fungal preparations and one small single-arm trial - establishes feasibility, not efficacy; plant- and algal-derived polysaccharides remain preclinical or clinically preliminary. Conformational analytics, machine-learning-assisted modelling and engineered delivery may address them.
PMID:
43039530
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0